New Non-Hodgkin's Lymphoma Clinical Trial: UF-KURE19 CAR-T cells for Non-Hodgkin's Lymphom
This trial will use the patient's own T cells that have been modified to target cancer by a inactive lentivirus. This is a shorter process than other CAR-T cells and has not been demonstrated to be safe. This is a Phase 1 trial recruiting patients with at least one measurable lesion according to Lugano Revised Response Criteria for Malignant Lymphoma.
00:00:16 What is the time commitment for this trial?
00:00:28 Who is eligible to enroll?
00:00:59 Where is the trial based?
Discover more information about the trial and apply through Power here: http://bit.ly/3VgWLEO
#NonHodgkinsLymphoma #NonHodgkinsLymphomaclinicaltrials #NonHodgkinsLymphomaresearch #NonHodgkinsLymphomatreatment #NonHodgkinsLymphomastudy #NonHodgkinsLymphomatrials #clinicaltrials #UFKURE19CARTcells
-
Category
No comments found